All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
31 - 40 of 53 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Presentation
Phase I trial of DLL3/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with DLL3-positive tumours: patients with LCNEC-L
Author(s): Wermke et et al.
Phase I Trial of DLL3/CD3 IgG-like T-cell Engager Obrixtamig (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC-L
Author(s): Wermke et al.
Target Engagement and Saturating Effects demonstrated with quantitative 89Zr-PET imaging for the Therapeutic Anti-SIRPα Antibody BI 765063
Author(s): Pouw et al.
Updated data from a Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumours: focus on extrapulmonary neuroendocrine carcinomas
Author(s): Capdevila et al.
Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumours: focus on extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
Phase I dose escalation trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients with DLL3+ tumors: focus on SCLC and LCNEC
Author(s): Wermke et al.
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3/CD3 IgG-like T-cell engager, in patients with DLL3-positive small-cell lung cancer and neuroendocrine carcinoma
Author(s): Wermke et al.
Infographic
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas of genitourinary origin with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Navarro-Gorro et al.
DAREON®-7: phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Chauhan et al.